CN118434419A - 类鸦片用于治疗自闭症谱系障碍的用途 - Google Patents

类鸦片用于治疗自闭症谱系障碍的用途 Download PDF

Info

Publication number
CN118434419A
CN118434419A CN202280084611.1A CN202280084611A CN118434419A CN 118434419 A CN118434419 A CN 118434419A CN 202280084611 A CN202280084611 A CN 202280084611A CN 118434419 A CN118434419 A CN 118434419A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
buprenorphine
morphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084611.1A
Other languages
English (en)
Chinese (zh)
Inventor
吾郷由希夫
山川英训
中邨笃史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
University of Osaka NUC
Original Assignee
Osaka University NUC
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Shionogi and Co Ltd filed Critical Osaka University NUC
Publication of CN118434419A publication Critical patent/CN118434419A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280084611.1A 2021-12-21 2022-12-21 类鸦片用于治疗自闭症谱系障碍的用途 Pending CN118434419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021206572 2021-12-21
JP2021-206572 2021-12-21
PCT/JP2022/047004 WO2023120551A1 (ja) 2021-12-21 2022-12-21 自閉スペクトラム症治療のためのオピオイドの使用

Publications (1)

Publication Number Publication Date
CN118434419A true CN118434419A (zh) 2024-08-02

Family

ID=86902678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084611.1A Pending CN118434419A (zh) 2021-12-21 2022-12-21 类鸦片用于治疗自闭症谱系障碍的用途

Country Status (6)

Country Link
US (1) US20250073226A1 (https=)
EP (1) EP4454649A4 (https=)
JP (1) JPWO2023120551A1 (https=)
CN (1) CN118434419A (https=)
TW (1) TW202329963A (https=)
WO (1) WO2023120551A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5931884B2 (ja) * 2010-10-07 2016-06-08 カリフォルニア インスティチュート オブ テクノロジー 自閉症の生菌療法
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
EP2859890A3 (en) * 2011-10-31 2015-08-05 The Johns Hopkins University Methods and compositions for treatment of autism
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US11491144B2 (en) * 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
US11160843B2 (en) 2018-04-30 2021-11-02 Yale University Oxytocin and opioid antagonists for treatment of social dysfunction disorder

Also Published As

Publication number Publication date
TW202329963A (zh) 2023-08-01
EP4454649A4 (en) 2025-11-26
EP4454649A1 (en) 2024-10-30
JPWO2023120551A1 (https=) 2023-06-29
WO2023120551A1 (ja) 2023-06-29
US20250073226A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
Pasquier Autophagy inhibitors
JP2021138765A (ja) 経粘膜吸収のための組成物および方法
EP3209298B1 (en) Compositions for treating insomnia
EP1063995B1 (en) Combination for the treatment of alcohol dependence containing an opioid antagonist and a nmda receptor complex modulator
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
NO330626B1 (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og quinidin for behandling av neurologiske forstyrrelser
KR20150002640A (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
JP2024102139A (ja) （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
RU2690685C2 (ru) Фармацевтические композиции, содержащие алпелисиб
CN113395962A (zh) 加波沙朵用于降低自杀风险和快速缓解抑郁症
CA3083341C (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP2958573B1 (en) Pharmaceutical formulations of nitrite and uses thereof
US20070184490A1 (en) Neuronal nicotinic receptor ligands and their use
CN112236140A (zh) 用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案
CA3198142A1 (en) Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
Westerling et al. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers
US20090060871A1 (en) Administration of agonist-antagonist in opioid-dependent patients
CN112714765A (zh) Gabaa受体配体
CN118434419A (zh) 类鸦片用于治疗自闭症谱系障碍的用途
AU2014239651A1 (en) Method of treating vitamin B12 deficiency
CN102600146A (zh) 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
AU2008334933B2 (en) Method and composition for treating a serotonin receptor-mediated condition
KR20230041006A (ko) 오피오이드 사용 감소 치료에 사용하기 위한 mglur5 길항제 마보글루란트
EP3270923B1 (en) Therapeutic agent for frontal lobe dysfunction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination